About this episode
This episode explores innovative approaches to hair loss treatment with insights from industry experts.
In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Daniel Gil , CEO, Pelage Pharmaceuticals Francisco Ramírez-Valle , Senior Vice President, Immunology Discovery, Eli Lilly Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
People in this episode
Host: Jennifer C. Smith-Parker
Guests: Daniel Gil, Francisco Ramírez-Valle
Topics covered
- hair loss treatment
- regenerative medicine
- immunology
- pharmaceutical innovation
- dormant follicles
Keywords
- hair loss
- treatment
- regenerative approach
- dormant follicles
- immunology
- pharmaceuticals
Mentioned in this episode
Organizations: Pelage Pharmaceuticals, Eli Lilly
More episodes of BioSpace
- Portugal, Spain and the new biotech frontier · June 10, 2026 · 21 min
- Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence · June 10, 2026 · 25 min
- ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck · June 3, 2026 · 27 min
- France’s biotech ecosystem: science, capital and scale · May 28, 2026 · 21 min
- Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds · May 27, 2026 · 25 min
- Inside Germany’s biotech capital infrastructure and innovation engine · May 21, 2026 · 23 min
Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.